VDR and triple-A syndrome: Martorell et al. reported that VDR, a TF associated with anti-inflammation and anti-proliferation, interacts with RXRα and inhibits the activation of MAPK pathway, VEGF expression, and ECM degradation in VECs, exhibiting anti-inflammatory and anti-neovascularization effects, thereby inhibiting AAA progression (84).